BioAge Labs (NASDAQ:BIOA) Shares Gap Down – Here’s Why

by · The Cerbat Gem

BioAge Labs, Inc. (NASDAQ:BIOA – Get Free Report) shares gapped down before the market opened on Wednesday . The stock had previously closed at $21.32, but opened at $20.13. BioAge Labs shares last traded at $21.0340, with a volume of 218,161 shares changing hands.

Analyst Upgrades and Downgrades

Several equities analysts have recently commented on the stock. Citigroup upped their price objective on shares of BioAge Labs from $10.00 to $15.00 and gave the company a “buy” rating in a research note on Wednesday, October 29th. Weiss Ratings restated a “sell (d-)” rating on shares of BioAge Labs in a report on Thursday, October 30th. Finally, Wall Street Zen upgraded BioAge Labs from a “sell” rating to a “hold” rating in a report on Sunday. One analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the company currently has an average rating of “Hold” and a consensus target price of $15.00.

Read Our Latest Analysis on BioAge Labs

BioAge Labs Stock Performance

The company has a 50-day simple moving average of $12.74 and a two-hundred day simple moving average of $7.92. The firm has a market capitalization of $712.19 million, a P/E ratio of -13.13 and a beta of 1.38.

BioAge Labs (NASDAQ:BIOA – Get Free Report) last released its quarterly earnings results on Thursday, November 6th. The company reported ($0.56) earnings per share for the quarter, beating the consensus estimate of ($0.67) by $0.11. The firm had revenue of $2.05 million for the quarter.

Insider Buying and Selling

In related news, insider Paul D. Rubin sold 68,897 shares of the stock in a transaction dated Thursday, December 4th. The shares were sold at an average price of $10.19, for a total value of $702,060.43. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, CFO Dov A. Md Goldstein sold 27,000 shares of the business’s stock in a transaction dated Tuesday, January 13th. The stock was sold at an average price of $19.70, for a total transaction of $531,900.00. Following the sale, the chief financial officer directly owned 22,408 shares in the company, valued at $441,437.60. The trade was a 54.65% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 347,004 shares of company stock worth $5,673,859 in the last three months. 20.82% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Bank of America Corp DE boosted its stake in BioAge Labs by 46.3% in the 3rd quarter. Bank of America Corp DE now owns 11,119 shares of the company’s stock worth $65,000 after purchasing an additional 3,517 shares in the last quarter. Vontobel Holding Ltd. raised its holdings in BioAge Labs by 36.4% in the third quarter. Vontobel Holding Ltd. now owns 15,000 shares of the company’s stock worth $88,000 after buying an additional 4,000 shares during the last quarter. Russell Investments Group Ltd. purchased a new position in BioAge Labs in the third quarter worth about $27,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its stake in shares of BioAge Labs by 85.6% in the second quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 12,955 shares of the company’s stock worth $54,000 after buying an additional 5,976 shares in the last quarter. Finally, Police & Firemen s Retirement System of New Jersey purchased a new stake in shares of BioAge Labs during the second quarter valued at approximately $27,000.

BioAge Labs Company Profile

(Get Free Report)

BioAge Labs (NASDAQ: BIOA) is a clinical-stage biotechnology company focused on discovering and developing therapies that address age-associated diseases. The company leverages its proprietary analytics platform to mine large-scale human biological data for insights into the molecular mechanisms of aging. By targeting fundamental aging pathways, BioAge aims to create interventions that extend healthspan and treat conditions that disproportionately affect older populations.

At the core of BioAge’s operations is its integrated drug discovery platform, which combines human omics datasets, machine learning algorithms and experimental validation to identify novel drug targets.

See Also